Leerink Partners Maintains Outperform on Belite Bio, Raises Price Target to $215

Benzinga · 18h ago
Leerink Partners analyst Marc Goodman maintains Belite Bio (NASDAQ:BLTE) with a Outperform and raises the price target from $185 to $215.